| INTRODUCTION
The introduction of direct-acting antivirals (DAA) has revolutionized treatment of chronic hepatitis C in terms of tolerability and sustained virological response (SVR) rates. 1, 2 Successful DAA treatment is associated with improved liver function, 3, 4 quality of life, 5 as well as reduced risk of decompensated liver disease 6 and portal hypertension. 7 IFN-based treatment regimens have a mode of action that is fundamentally different from DAA therapy. Therefore, our knowledge regarding the improvement of liver function, regression of cirrhosis and portal hypertension, as well as incidence of hepatocellular carcinoma after HCV cure cannot simply be transferred from the IFN-based to the IFN-free era.
After IFN-based SVR there is a decreased but not abrogated risk of HCC. [8] [9] [10] [11] [12] [13] The presence of liver cirrhosis, higher age and diabetes mellitus type 2 are well-known risk factors for the development of post-SVR HCC.
14 Emerging data raised suspicion of an increased risk of recurrence of curatively treated HCC after DAA therapy, 15, 16 although both studies lacked an untreated control group. There was an unexpectedly high recurrence rate of almost 30% in a short-term observation period of 6 months. On the contrary the French ANRS study and the Italian RESIST HCV cohort did not show an increased risk regarding HCC recurrence after DAA therapy. 17, 18 The development of de novo HCC after DAA must be examined separately from HCC recurrence because it presents a fundamentally different setting. Incidence of de novo HCC in DAA-treated cirrhotic patients was reported to be 3.2% over 6 months, 16 5.2% over 48 weeks 19 and 4.7% over 15 months. 6 The latter study showed a significantly decreased rate of HCC in patients with SVR compared to patients with treatment failure. The other studies had no control group.
The aim of this study was to address the yet unanswered question whether DAA-based antiviral treatment of chronic hepatitis C changes the short-term risk for de novo HCC. For reliable risk evaluation, we recruited an untreated historical control cohort treated at the same centre which had similar patient characteristics and was monitored with identical protocols.
2 | ME TH ODS
| Study population
This study included patients with chronic hepatitis C and liver cirrhosis which were recruited from the regular liver outpatient clinic of Hannover Medical School in Germany. This clinic follows patients without an option or immediate need for liver transplantation only.
Chronic hepatitis C was defined by documented HCV viremia for at least 6 months. Main criteria for cirrhosis were liver histology (F5 and F6 according to ISHAK-score), transient elastography (≥ 14.5 kPa) and morphological signs of cirrhosis in ultrasound, magnetic resonance imaging (MRI) and computer tomography (CT). If imaging gave no definite diagnosis of cirrhosis, additional clinical criteria of cirrhosis had to be present for confirmation: splenomegaly significant. This method was also used to identify factors potentially affecting the HCC rate. All variables were compared between the groups "HCC", "no HCC", respectively. 
| Ethics
The study was conducted in accordance to the Helsinki declaration.
The study protocol was approved by ethics committee of Hannover Medical School. All patients in the DAA-treated cohort gave informed consent to participate in the study. For the retrospective control cohort, all data were analysed after pseudoanonymization which is in line with ethics regulations of Hannover Medical School.
3 | RESULTS
| Patient characteristics
The DAA-treated patient cohort with chronic hepatitis C was generated according to the study flow chart in Figure 1A . Between Jan- Baseline characteristics were largely comparable between the two cohorts ( Figure 2A , log-rank P = .39). In the treated group, no new case of HCC occurred later than 450 days after treatment initiation.
A longer follow-up was available for 77 of 158 patients in the DAAtreated group (49%).
Moreover, death and liver transplantation were comparably frequent across the cohorts. Two patients (1.3%) died in the DAAtreated group vs 3 (1.6%) in the control group (P = .78) and 1 (.6%) vs 4 (2.2%) patients underwent liver transplantation (P = .24). Liver transplant-free survival was similar between groups as depicted in
Kaplan-Meier analysis and log-rank test ( Figure 2B , log-rank P = .42).
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| Factors associated with HCC development
Characteristics of patients who developed hepatocellular carcinoma and subjects who remained free of HCC are shown in Table 2 .
Based on univariate analysis the groups showed statistically signifi- Italy, Austria, the UK and the USA. 6, [15] [16] [17] 19, 20 Overall, these manuscripts described HCC incidences of about 4.7 to 6.6% per year in patients who were previously free of HCC. 6, [15] [16] [17] 19 In contrast, the risk for HCC recurrence was described to be much higher ranging between 8.8 and 13.3/100 person-years 17 to 68/100 person-years. 15 However, it is unclear how these HCC incidence and recurrence rates compare to untreated control groups which are challenging to identify. Considering the very high virological efficacy of novel HCV therapies which lead to improvement of liver function and a reduced risk of hepatic decompensation, 3, 21 it is meanwhile ethically impossible to design prospective randomized studies including an untreated control group. Thus, we selected a retrospective cohort of untreated cirrhotic HCV patients recruited at the same centre before January 2014 followed with similar screening strategies and with similar patient characteristics.
The median age, gender distribution, prevalence of diabetes mellitus and biochemical markers of liver function were comparable to previous multicentre cohorts. 22 It has to be noted that HCV-genotype distributions differ between European cohorts with higher prevalence of about 40% of genotype 3 in the UK 6 and more dominant genotype 1 infection in southern Europe. 15, 16 The genotype distribution in our cohort was between these two extremes with 14.6% of genotype 3 infections.
During the first 15 months after initiation of antiviral therapy there was no difference in the HCC incidence in patients receiving antiviral therapy as compared to the control group. The overall risk to develop HCC was 2.9 and 4.5/100 person-years in the two groups and therefore very well in line with the English and Italian experience 6, 16 and also with historical data of European cohorts followed after failure of IFN-based therapy. 9 Previous studies investigating HCC incidence after IFN-free therapy had a rather short follow-up of up to fifteen months. In contrast, we here provide follow-up data for up to 2. We also could not investigate if DAA treatment failure alters the HCC risk and did not study the risk of HCC recurrence in the context of IFN-free therapies. Furthermore, some patients receiving IFN-free DAA therapy had been treated with IFN-containing regimens before, as highlighted in the description of the patient cohort. As mentioned, patients were studied only after at least 6 months after the end of IFN-based therapies to exclude a prolonged off-treatment therapeutic effect. Still, previous interferon alpha therapy may have longer biological off-treatment effects.
This, however, would hold true for both study groups as the same percentage of patients had been previously treated with IFNa (both 68%).
In summary, IFN-free DAA therapy of patients with hepatitis C and liver cirrhosis does not alter the risk for hepatocellular carcinoma during the first one and a half years after initiation of antiviral therapy. Thus, regular HCC screening should be performed in all cirrhotic patients with hepatitis C regardless of the fact that they were treated with direct acting antivirals. 
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